139 related articles for article (PubMed ID: 38585879)
21. STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity.
Tabar MMM; Fathi M; Kazemi F; Bazregari G; Ghasemian A
Mol Biol Rep; 2024 Apr; 51(1):487. PubMed ID: 38578532
[TBL] [Abstract][Full Text] [Related]
22. Anticancer Effect of STING Agonist-Encapsulated Liposomes on Breast Cancer.
Zhang J; Cui X; Huang Y; Xu X; Feng C; Li J
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175150
[TBL] [Abstract][Full Text] [Related]
23. Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy.
Chen S; Peng A; Chen M; Zhan M
Front Oncol; 2022; 12():1093240. PubMed ID: 36741735
[TBL] [Abstract][Full Text] [Related]
24. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
[TBL] [Abstract][Full Text] [Related]
25. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
[TBL] [Abstract][Full Text] [Related]
26. A manganese-phenolic network platform amplifying STING activation to potentiate MRI guided cancer chemo-/chemodynamic/immune therapy.
Pang X; Fu C; Chen J; Su M; Wei R; Wang Y; Lin W; Wei X; Jiang X; Yang X; Yang H; Wang J; Yang R
Biomater Sci; 2023 May; 11(11):3840-3850. PubMed ID: 37074080
[TBL] [Abstract][Full Text] [Related]
27. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
Motedayen Aval L; Pease JE; Sharma R; Pinato DJ
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081170
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticle-Mediated STING Agonist Delivery for Enhanced Cancer Immunotherapy.
Zhou Q; Zhou Y; Li T; Ge Z
Macromol Biosci; 2021 Aug; 21(8):e2100133. PubMed ID: 34117839
[TBL] [Abstract][Full Text] [Related]
29. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.
Czapla J; Drzyzga A; Matuszczak S; Cichoń T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R
Front Oncol; 2023; 13():1249524. PubMed ID: 37655095
[TBL] [Abstract][Full Text] [Related]
30. Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
Garland KM; Sheehy TL; Wilson JT
Chem Rev; 2022 Mar; 122(6):5977-6039. PubMed ID: 35107989
[TBL] [Abstract][Full Text] [Related]
31. Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models.
Shi X; Shu L; Wang M; Yao J; Yao Q; Bian S; Chen X; Wan J; Zhang F; Zheng S; Wang H
Adv Sci (Weinh); 2023 May; 10(15):e2204890. PubMed ID: 37017572
[TBL] [Abstract][Full Text] [Related]
32. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.
Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188
[TBL] [Abstract][Full Text] [Related]
33. Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases.
Zhou S; Cheng F; Zhang Y; Su T; Zhu G
Acc Chem Res; 2023 Nov; 56(21):2933-2943. PubMed ID: 37802125
[TBL] [Abstract][Full Text] [Related]
34. Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis.
Go EJ; Yang H; Park W; Lee SJ; Han JH; Kong SJ; Lee WS; Han DK; Chon HJ; Kim C
Small; 2023 Oct; 19(43):e2300544. PubMed ID: 37381624
[TBL] [Abstract][Full Text] [Related]
35. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
[No Abstract] [Full Text] [Related]
36. Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy.
Cao L; Tian H; Fang M; Xu Z; Tang D; Chen J; Yin J; Xiao H; Shang K; Han H; Li X
Biomaterials; 2022 Nov; 290():121856. PubMed ID: 36306685
[TBL] [Abstract][Full Text] [Related]
37. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of tumor intrinsic BANF1 activates antitumor immune responses via cGAS-STING and enhances the efficacy of PD-1 blockade.
Wang M; Huang Y; Chen M; Wang W; Wu F; Zhong T; Chen X; Wang F; Li Y; Yu J; Wu M; Chen D
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37620043
[TBL] [Abstract][Full Text] [Related]
39. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.
Lemos H; Mohamed E; Huang L; Ou R; Pacholczyk G; Arbab AS; Munn D; Mellor AL
Cancer Res; 2016 Apr; 76(8):2076-81. PubMed ID: 26964621
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L
Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
